Dr. David B. Allison, PhD

Distinguished Professor at the Indiana University School of Public Health-Bloomington.

David is acting as an independent consultant to Ro and not on behalf of or representing Indiana University or any other organization.

Indiana University School of Public Health-Bloomington

Dr. Allison completed post-doctoral training at Johns Hopkins University School of Medicine and at the NIH-funded NY Obesity Research Center at St. Luke’s-Roosevelt Hospital and Columbia University. He has been on the faculty of Columbia University, University of Alabama at Birmingham, and is currently Distinguished Professor at Indiana University’s School of Public Health-Bloomington.

Wegovy Pill: What the Launch Means for You

Novo Nordisk's CEO is calling the US launch of oral Wegovy a record-breaking start. If you've been avoiding weekly injections, this development could change your options. Here's what the pill form of semaglutide actually means for patients.

How GLP-1 Drugs Are Changing Your Shopping Habits

People taking GLP-1 medications like semaglutide and tirzepatide are noticing real shifts in how they shop for food and clothing. Smaller appetites, changing taste preferences, and a slimmer body all have practical and financial implications. Here's what to expect and how to prepare.

Ozempic Made Kris Jenner Sick: What It Means for You

Kris Jenner recently shared that Ozempic made her severely ill before she found a medication that worked better for her. Her experience highlights something many patients face: not every GLP-1 medication works the same way for every person. Here's what that means if you're currently on or considering semaglutide.

GLP-1 Drugs Are Reshaping Weight Loss

GLP-1 receptor agonists like semaglutide and tirzepatide have moved weight loss treatment beyond willpower and dieting. This article explains what the scientific and cultural shift means for patients considering or already using these medications, including practical guidance on costs, providers, and what to ask your doctor.

State Employee GLP-1 Coverage Rules Are Changing

Several states are revising their employee health benefit rules around GLP-1 medications like semaglutide and tirzepatide for weight loss. If you're a state employee or on a government health plan, these changes could affect your out-of-pocket costs and access. Here's what you need to know.